Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Cerebellar rTMS and Physical Therapy for Cerebellar Ataxia
Not Applicable
Completed
- Conditions
- Spinocerebellar AtaxiasMultiple System Atrophy, Cerebellar Variant (Disorder)
- Interventions
- Device: Cerebellar repetitive transcranial magnetic stimulation
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT04595578
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT04591002
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
Application of Transcranial Direct Current Stimulation (tDCS) for Gait Function Improvement of Parkinson's Disease Patient
Not Applicable
Completed
- Conditions
- Parkinson Disease
- Interventions
- Device: Brain stimulationDevice: Treadmill gait training
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT04591236
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Early Mobilization in Ventilated SEpsis & Acute Respiratory Failure Study
Not Applicable
Completed
- Conditions
- Critically IllEarly Mobility
- Interventions
- Other: early mobilization
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT04582760
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Effect of Cerebral and Cerebellar rTMS in Stroke Patient
Not Applicable
Completed
- Conditions
- StrokerTMSMotor RecoveryRepetitive Transcranial Magnetic Stimulation
- Interventions
- Procedure: Repetitive transcranial magnetic stimulation
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT04570774
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Mobile Application Using the PRO-CTCAE to Improve Patients' Participation in Symptom Management During Treatment.
Not Applicable
- Conditions
- Neoplasms
- Interventions
- Other: ePRO-CTCAE application
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 222
- Registration Number
- NCT04568278
- Locations
- 🇰🇷
Danbee Kang, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: 80mg Osimertinib
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 73
- Registration Number
- NCT04563871
- Locations
- 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Study on Brain Activity During Transcranial Direct Current Stimulation in Stroke Patients
Not Applicable
Completed
- Conditions
- Stroke
- Interventions
- Device: Transcranial direct current simulation
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04549753
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Phase 2
Withdrawn
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Drug: Gemcitabine, Cisplatin, and Nab-Paclitaxe
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT04546828
Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery
Phase 3
- Conditions
- Chronic Obstructive Pulmonary DiseaseNon Small Cell Lung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 204
- Registration Number
- NCT04536675
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath